AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Align Technology

Teladoc

As the pandemic draws down, some companies will get a real boost from the "new normal."

These 3 Healthcare Stocks Could Be on Top in 2021

More data is needed from AstraZeneca's Covid vaccine trials beyond what was presented in a press release, experts from the WHO and Oxford University said.

Oxford, WHO scientists say more data needed on AstraZeneca's Covid vaccine trials

The World Health Organisation (WHO) has said it needs "more than a press release" about the Oxford/AstraZeneca vaccine in order to evaluate trial results.

WHO needs 'more than press release' on Oxford vaccine, says immunisations chief

Suspected North Korean hackers have tried to break into the systems of British drugmaker AstraZeneca in recent weeks, two people with knowledge of the matter told Reuters, as the company races to deploy its vaccine for the COVID-19 virus.

Exclusive: Suspected North Korean hackers targeted COVID vaccine maker AstraZeneca - sources

Britain has asked its medicine regulator to assess the vaccine for a temporary supply, which could mean it's rolled out in the country before the end of the year.

Britain tries to cool AstraZeneca concerns as its CEO touts a new vaccine trial

In a statement on Thursday, CEO Pascal Soriot of AstraZeneca plc (LON: AZN) expressed plans of launching a new global trial that will study the efficacy of its Coronavirus vaccine on a lower dosage. AstraZeneca opened more than 1% down on Friday.

AstraZeneca to launch a new global trial for its COVID-19 vaccine

British housing minister Robert Jenrick said there was no reason for anyone to be concerned about the data behind the Oxford and AstraZeneca vaccine and said the independent regulator would work to assess it.

No reason to worry about Oxford/Astra vaccine, UK minister says

AstraZeneca is likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine using a lower dosage, its chief executive was quoted as saying on Thursday amid questions over the results of its late-stage study.

AstraZeneca CEO expects to run new global trial of COVID-19 vaccine: Bloomberg

The British government's Chief Scientific Adviser Patrick Vallance said on Thursday the main point about the AstraZeneca vaccine against COVID-19 was that it worked, when asked about doubts that have been raised about the vaccine.

Top UK scientific adviser says AstraZeneca vaccine works

The company's CEO said the new trial will be conducted outside the U.S. and its data may not be adequate to lead to approval from the FDA.

AstraZeneca May Conduct Additional Trial For Covid-19 Vaccine After Acknowledging Errors In Initial Trial

Experts' trust in the validity of AstraZeneca's reported COVID-19 data have eroded quickly in just a few days. The company reported Monday that its coronavirus vaccine was up to 90% effective based on preliminary results from a study of 23,000 volunteers in Brazil and the UK.

AstraZeneca will likely re-test its COVID-19 vaccine, CEO says after admitting an error in the first trial that may have skewed results

AstraZeneca's CEO told Bloomberg that the pharmaceutical company will likely conduct another global trial of the effectiveness of its COVID-19 vaccine trial, following the disclosure that the more effective dosage in the existing Phase 3 clinical trial was actually administered by accident. AstraZeneca and its partner the University of Oxford reported interim results that showed […]

AstraZeneca says it will likely do another study of COVID-19 vaccine after accidental lower dose shows higher efficacy

AstraZeneca - the company collaborating with Oxford University on a coronavirus vaccine - is set to run an extra trial of the jab.

AstraZeneca to run extra trial of COVID vaccine developed with Oxford University

A roll-out of the Oxford/AstraZeneca vaccine in the UK could be a step closer after the regulator was formally asked by the government to assess the Pfizer/BioNTech vaccine.

UK regulator to assess Oxford vaccine in 'first step' towards roll-out

“We believe that this product will never be licensed in the U.S.,” one group of critical U.S.-based analysts wrote this week.

AstraZeneca and Oxford defend Covid vaccine trials after questions raised in the U.S.

AstraZeneca and the University of Oxford on Wednesday acknowledged a dosing error in their COVID-19 vaccine trial — and some health experts have said it has eroded their confidence in the shot. The COVID-19 vaccine is on average 70% effective, according to the latest large-scale trial results announced Monday. The vaccine was found to be 62% effective in those who had two full doses, but rose to 90% effective in those who had a half-dosage in their first shot. 

AstraZeneca admits the best results in its COVID-19 vaccine study came from a dosing error, and experts are raising new questions about the shot

Moderna

Pfizer

Which leading coronavirus vaccine candidate looks best so far?

Here's How the Top 3 Coronavirus Vaccine Candidates Stack Up

Could AstraZeneca's Coronavirus Vaccine Beat Pfizer and Moderna?

Abbott Labs

Gilead Sciences

Inovio Pharmaceuticals

Johnson & Johnson

Novavax

Sorrento Therapeutics Inc

Regeneron Pharmaceuticals

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here's how this affects other Covid-19-related biotech stocks. The post 7 Biotech Stocks That Are Locked in the Race for a Vaccine appeared first on InvestorPlace.

7 Biotech Stocks That Are Locked in the Race for a Vaccine

Interim data from late-stage studies on AstraZeneca (AZN) COVID-19 vaccine shows that the candidate was, on an average, about 70% effective in preventing COVID-19.

How Does AstraZeneca's COVID-19 Vaccine Data Compare to Others'?

BioNTech SE

Positive developments related to coronavirus vaccine candidates have supported stock markets in November. Three leading coronavirus vaccine candidates achieve encouraging efficacy rate.

3 Coronavirus Vaccine Makers Near Finish Line in November

Corning

West Pharmaceutical Services

Even when a coronavirus vaccine is ready, distribution could be a challenge -- but recent innovations in medical glass could benefit the public and investors alike.

The Vaccines Are Almost Ready, but the Challenges Are Only Beginning

Requests for Emergency Use Authorization and formal FDA approvals are next on the agenda.

What to Watch for Next in the Coronavirus Vaccine Race

AstraZeneca's (AZN) Imfizni is now available in monthly, fixed-dose regimen as alternative to twice-monthly, weight-based regimen for all three approved indications.

AstraZeneca's (AZN) sBLA for New Imfinzi Dosage Gets Approval

AstraZeneca said its University of Oxford-partnered coronavirus vaccine was 70% effective, on average, in a study — leading shares to dive Monday. Some patients saw 90% effectiveness.

News for AstraZeneca Stock (AZN)